Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
The program includes 10 weeks of education and counseling with 5 modules and 3 months’ of follow-up.
Responses in cancer patients were noninferior to responses in patients without cancer.
The progression-free and overall survival benefits with lenvatinib plus pembrolizumab were observed across subgroups.
The 12-month progression-free survival rate was 35.9% with sunitinib and 18.9% with placebo.
The rate of perioperative distant metastases was significantly lower with CapeOx than with CRT.
Researchers sought to determine whether interleukin-6 levels would be predictive of survival in patients with Hodgkin lymphoma receiving nivolumab.
The median PFS was 8.0 months with TARE and 7.2 months with chemotherapy alone.
At data cutoff, 562 of 626 patients enrolled in the study were eligible for primary endpoint assessment.
The addition of nivolumab to chemotherapy demonstrated continuing improved survival compared with chemotherapy alone after 24 months of follow-up.
